Page last updated: 2024-12-08

oxyluciferin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID135398698
CHEBI ID16792
SCHEMBL ID889204
SCHEMBL ID14064041
SCHEMBL ID16155845
MeSH IDM0063498

Synonyms (26)

Synonym
CHEBI:16792
2-(6-hydroxy-1,3-benzothiazol-2-yl)-1,3-thiazol-4(5h)-one
OLU ,
oxyluciferin
C03797
4,5-dihydro-2-(6-hydroxy-1,3-benzothiazol-2-yl)thiazol-4-one
firefly oxyluciferin
excited state firefly oxyluciferin
DB08326
4(5h)-thiazolone, 2-(6-hydroxy-2-benzothiazolyl)-
17002-50-5
SCHEMBL889204
SCHEMBL14064041
SCHEMBL16155845
DTXSID70735852
2-(4-oxo-1,3-thiazolidin-2-ylidene)-1,3-benzothiazol-6(2h)-one
ground state firefly oxyluciferin
2-(4-oxo-1,3-thiazolidin-2-ylidene)-1,3-benzothiazol-6-one
Q27097544
2-(6-hydroxybenzo[d]thiazol-2-yl)thiazol-4(5h)-one
2-(6-hydroxy-2-benzothiazolyl)-4(5h)-thiazolone
2-(6-oxidanyl-1,3-benzothiazol-2-yl)-1,3-thiazol-4-one
2-thiazolin-4-one, 2-(6-hydroxy-2-benzothiazolyl)-
8t3z7x2y9g ,
unii-8t3z7x2y9g
PD004503
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
oxidized luciferinsnull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
Photinus luciferinA 1,3-thiazolemonocarboxylic acid consisting of 3,5-dihydrothiophene-4-carboxylic acid having a 6-hydroxybenzothiazol-2-yl group at the 2-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (80)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (2.50)18.7374
1990's3 (3.75)18.2507
2000's15 (18.75)29.6817
2010's56 (70.00)24.3611
2020's4 (5.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (4.71%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other81 (95.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]